PRIME-HCC: ipilimumab and nivolumab in liver cancer

David Pinato, MD, MRes, PhD, Imperial College London, London, UK, shares an update on the Phase Ib PRIME-HCC trial (NCT03682276) of neoadjuvant ipilimumab and nivolumab before liver resection in patients with hepatocellular cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

• Catégorie